<- Go Home
Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Market Cap
EUR 215.2M
Volume
55.9K
Cash and Equivalents
EUR 10.4M
EBITDA
-EUR 98.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 18.2M
Profit Margin
94.38%
52 Week High
EUR 4.30
52 Week Low
EUR 1.43
Dividend
N/A
Price / Book Value
-1.49
Price / Earnings
-1.09
Price / Tangible Book Value
-1.48
Enterprise Value
EUR 278.2M
Enterprise Value / EBITDA
-2.81
Operating Income
-EUR 100.0M
Return on Equity
240.26%
Return on Assets
-113.34
Cash and Short Term Investments
EUR 10.4M
Debt
EUR 73.4M
Equity
-EUR 79.1M
Revenue
EUR 19.3M
Unlevered FCF
-EUR 44.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium